The HER-2/neu oncogene in tumors of the gastrointestinal tract
The HER-2/neu oncogene in tumors of the gastrointestinal tract
复制标题
DOI：
10.1081/cnv-100103852
复制
发表时间：
2001-01-01
影响因子：
2.4
通讯作者：
McKenna, BJ
中科院分区：
文献类型：
--
作者：
Ross, JS;McKenna, BJ
HER-2/neu 癌基因定位于 17q 染色体，与表皮生长因子受体具有显着同源性。由于 HER-2/neu 在治疗选择中的潜在作用，HER-2/neu 检测在乳腺癌中已达到接近实践标准的状态：人们对 HER-2/neu 作为胃肠道肿瘤的预后因素和治疗靶点非常感兴趣。在这篇关于食管鳞状细胞癌和食管、胃和结肠腺癌中 HER-2/neu 表达的综述中，HER-2/neu 的表达范围从 0% 到 83% 很可能反映了方法和试剂的差异，以及与患者选择相关的研究偏倚（即早期与晚期疾病）。对于食管鳞状细胞癌，关于 HER-2/neu 表达的预后意义的信息很少。对于与巴雷特食管相关的腺癌，存在相互矛盾的数据。然而，大多数可用信息表明该标志物具有重要的预后价值。在胃腺癌中，广泛的表达范围可能真正反映了患者的选择，因为 HER-2/neu 阳性似乎与晚期而非侵袭有限的早期疾病相关。大多数研究都支持 HER-2/neu 状态对该肿瘤具有显着的预后价值：最后，根据当前发表的文献判断，在结直肠癌中 HER-2/neu 过度表达似乎也是一个显着的不良结果指标。总之，鉴于 HER-2/neu 蛋白过度表达或基因扩增与大约四分之一的胃肠道恶性肿瘤相关，因此设计用于采用标志物治疗选择的策略似乎是有必要的。在接下来的几年中，看到这些肿瘤采用抗 HER-2/neu 疗法（如赫赛汀 (TM)）进行治疗也就不足为奇了，这些肿瘤可能最初与其他药物联合治疗晚期疾病患者，也可能在佐剂中用于患有高风险病变的个体？环境。
The HER-2/neu oncogene is localized to chromosome 17q and shares significant homology with the epidermal growth factor receptor As a result of ifs potential role in the selection of therapy, HER-2/neu testing has reached near-standard-of-practice status in breast cancer: There is considerable interest in HER-2/neu as a prognostic factor and target of therapy in tumors elf the gastrointestinal tract. In this review of HER-2/neu expression in esophageal squamous cell carcinoma and adenocarcinomas of the esophagus, stomach, and colon, a wide range of expression of HER-2/neu from 0 to 83% likely reflects both differences in methods and reagents, as well as study bias associated with patient selection (i.e., early versus advanced disease). For esophageal squamous cell carcinoma, little information exists as to the prognostic significance of HER-2/neu expression. In adenocarcinoma associated with Barrett's esophagus there is contradictory data. However, most of the information available indicates that this marker hers significant prognostic value. In gastric adenocarcinoma, the wide expression range may truly reflect patient selection because HER-2/neu positivity appears linked to advanced rather than early disease with limited invasion. The majority of studies favor a significant prognostic value of HER-2/neu status for this tumor: Finally in colorectal cancer HER-2/neu overexpression also appears to be a significant adverse outcome indicator as judged by the current published literature. In conclusion, given that either HER-2/neu protein overexpression or gene amplification is associated with approximately one-fourth of all gastrointestinal tract malignancies, strategies designed to employ the marker therapy selection appear warranted. During the next several years it will not be surprising to see these tumors treated with antiHER-2/neu modalities such as Herceptin (TM), likely in combination with other agents initially Sor patients with advanced disease, and possibly, for individuals with high-risk lesions in an adjuvant? setting.